Which has higher valuation & earnings, NVCR or NPCE?

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.08 -$136.23M -$1.30 N/A NeuroPace $99.99M 5.07 -$21.47M -$0.65 N/A

Is NVCR or NPCE more profitable?

NovoCure has a net margin of -21.25% compared to NeuroPace's net margin of -21.67%. NovoCure's return on equity of -44.00% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% NeuroPace -21.67% -108.20% -18.50%

Does the media prefer NVCR or NPCE?

In the previous week, NeuroPace had 1 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat NeuroPace's score of 0.34 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NPCE or INSP?

In the previous week, Inspire Medical Systems had 25 more articles in the media than NeuroPace. MarketBeat recorded 28 mentions for Inspire Medical Systems and 3 mentions for NeuroPace. Inspire Medical Systems' average media sentiment score of 1.31 beat NeuroPace's score of 0.34 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspire Medical Systems 20 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ENOV or NPCE?

NeuroPace has lower revenue, but higher earnings than Enovis. NeuroPace is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.62 -$1.18B -$19.26 N/A NeuroPace $99.99M 5.07 -$21.47M -$0.65 N/A

Is ENOV or NPCE more profitable?

NeuroPace has a net margin of -21.67% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% NeuroPace -21.67% -108.20% -18.50%

Does the media refer more to ENOV or NPCE?

In the previous week, Enovis had 21 more articles in the media than NeuroPace. MarketBeat recorded 24 mentions for Enovis and 3 mentions for NeuroPace. Enovis' average media sentiment score of 0.47 beat NeuroPace's score of 0.34 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 3 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NPCE or OMCL?

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 5.07 -$21.47M -$0.65 N/A Omnicell $1.18B 1.43 $2.05M $0.84 44.42

Is NPCE or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -21.67%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% Omnicell 3.13% 5.66% 3.57%

Does the media favor NPCE or OMCL?

In the previous week, NeuroPace and NeuroPace both had 3 articles in the media. Omnicell's average media sentiment score of 0.42 beat NeuroPace's score of 0.34 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ATEC or NPCE?

NeuroPace has lower revenue, but higher earnings than Alphatec. NeuroPace is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alphatec $764.16M 1.92 -$143.36M -$0.71 N/A NeuroPace $99.99M 5.07 -$21.47M -$0.65 N/A

Is ATEC or NPCE more profitable?

Alphatec has a net margin of -13.49% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Alphatec -13.49% -6,752.24% -13.88% NeuroPace -21.67% -108.20% -18.50%

Does the media prefer ATEC or NPCE?

In the previous week, Alphatec had 14 more articles in the media than NeuroPace. MarketBeat recorded 17 mentions for Alphatec and 3 mentions for NeuroPace. Alphatec's average media sentiment score of 0.57 beat NeuroPace's score of 0.34 indicating that Alphatec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphatec 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroPace (NPCE) Competitors

$14.88 +0.05 (+0.34%)

As of 04:00 PM Eastern

Compare

NPCE vs. NVCR, INSP, ENOV, OMCL, and ATEC

Should you buy NeuroPace stock or one of its competitors? NeuroPace's main competitors and comparable companies include NovoCure (NVCR), Inspire Medical Systems (INSP), Enovis (ENOV), Omnicell (OMCL), and Alphatec (ATEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroPace compare to NovoCure?

NovoCure (NASDAQ:NVCR) and NeuroPace (NASDAQ:NPCE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NovoCure has a net margin of -21.25% compared to NeuroPace's net margin of -21.67%. NovoCure's return on equity of -44.00% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
NeuroPace	-21.67%	-108.20%	-18.50%

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.08	-$136.23M	-$1.30	N/A
NeuroPace	$99.99M	5.07	-$21.47M	-$0.65	N/A

NovoCure has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

NovoCure presently has a consensus target price of $21.20, suggesting a potential upside of 22.47%. NeuroPace has a consensus target price of $19.29, suggesting a potential upside of 29.61%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
NeuroPace	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, NeuroPace had 1 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat NeuroPace's score of 0.34 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeuroPace beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Inspire Medical Systems?

NeuroPace (NASDAQ:NPCE) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

NeuroPace currently has a consensus target price of $19.29, indicating a potential upside of 29.61%. Inspire Medical Systems has a consensus target price of $68.00, indicating a potential upside of 13.64%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Inspire Medical Systems	3 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.10

Inspire Medical Systems has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.07	-$21.47M	-$0.65	N/A
Inspire Medical Systems	$911.98M	1.90	$145.42M	$4.62	12.95

Inspire Medical Systems has a net margin of 15.03% compared to NeuroPace's net margin of -21.67%. Inspire Medical Systems' return on equity of 8.64% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Inspire Medical Systems	15.03%	8.64%	7.45%

NeuroPace has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Inspire Medical Systems had 25 more articles in the media than NeuroPace. MarketBeat recorded 28 mentions for Inspire Medical Systems and 3 mentions for NeuroPace. Inspire Medical Systems' average media sentiment score of 1.31 beat NeuroPace's score of 0.34 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspire Medical Systems	20 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 19.2% of NeuroPace shares are owned by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Inspire Medical Systems beats NeuroPace on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Enovis?

Enovis (NYSE:ENOV) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Enovis had 21 more articles in the media than NeuroPace. MarketBeat recorded 24 mentions for Enovis and 3 mentions for NeuroPace. Enovis' average media sentiment score of 0.47 beat NeuroPace's score of 0.34 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	3 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enovis presently has a consensus target price of $42.00, suggesting a potential upside of 73.20%. NeuroPace has a consensus target price of $19.29, suggesting a potential upside of 29.61%. Given Enovis' higher possible upside, equities analysts plainly believe Enovis is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
NeuroPace	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

NeuroPace has lower revenue, but higher earnings than Enovis. NeuroPace is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.62	-$1.18B	-$19.26	N/A
NeuroPace	$99.99M	5.07	-$21.47M	-$0.65	N/A

98.5% of Enovis shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NeuroPace has a net margin of -21.67% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
NeuroPace	-21.67%	-108.20%	-18.50%

Enovis has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Summary

Enovis beats NeuroPace on 9 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Omnicell?

NeuroPace (NASDAQ:NPCE) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

NeuroPace has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, NeuroPace and NeuroPace both had 3 articles in the media. Omnicell's average media sentiment score of 0.42 beat NeuroPace's score of 0.34 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -21.67%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Omnicell	3.13%	5.66%	3.57%

NeuroPace currently has a consensus target price of $19.29, suggesting a potential upside of 29.61%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 55.07%. Given Omnicell's higher probable upside, analysts plainly believe Omnicell is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.07	-$21.47M	-$0.65	N/A
Omnicell	$1.18B	1.43	$2.05M	$0.84	44.42

Summary

Omnicell beats NeuroPace on 11 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Alphatec?

Alphatec (NASDAQ:ATEC) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Alphatec had 14 more articles in the media than NeuroPace. MarketBeat recorded 17 mentions for Alphatec and 3 mentions for NeuroPace. Alphatec's average media sentiment score of 0.57 beat NeuroPace's score of 0.34 indicating that Alphatec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphatec	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has lower revenue, but higher earnings than Alphatec. NeuroPace is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$764.16M	1.92	-$143.36M	-$0.71	N/A
NeuroPace	$99.99M	5.07	-$21.47M	-$0.65	N/A

66.4% of Alphatec shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 13.5% of Alphatec shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alphatec presently has a consensus target price of $17.40, suggesting a potential upside of 83.35%. NeuroPace has a consensus target price of $19.29, suggesting a potential upside of 29.61%. Given Alphatec's higher possible upside, equities analysts plainly believe Alphatec is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
NeuroPace	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

Alphatec has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Alphatec has a net margin of -13.49% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-13.49%	-6,752.24%	-13.88%
NeuroPace	-21.67%	-108.20%	-18.50%

Summary

Alphatec and NeuroPace tied by winning 8 of the 16 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$507.26M	$5.79B	$7.06B	$12.95B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-22.89	24.71	269.75	24.74
Price / Sales	5.07	67.44	652.34	108.60
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	26.11	6.21	11.27	6.42
Net Income	-$21.47M	$147.87M	$3.45B	$347.12M
7 Day Performance	10.22%	3.40%	3.57%	2.48%
1 Month Performance	-13.03%	1.67%	-0.58%	-1.04%
1 Year Performance	65.70%	6.26%	77.53%	23.22%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	2.7175 of 5 stars	$14.88 +0.3%	$19.29 +29.6%	+65.1%	$507.26M	$99.99M	N/A	170	Upcoming Earnings
NVCR NovoCure	3.0412 of 5 stars	$15.97 +4.2%	$21.20 +32.8%	+47.3%	$1.86B	$655.35M	N/A	1,605	Analyst Upgrade
INSP Inspire Medical Systems	4.1158 of 5 stars	$62.97 +20.6%	$71.67 +13.8%	-24.1%	$1.82B	$911.98M	14.03	1,333	Positive News Earnings Report
ENOV Enovis	4.5385 of 5 stars	$30.96 -1.5%	$41.86 +35.2%	-6.3%	$1.78B	$2.25B	N/A	7,802	Earnings Report Analyst Forecast
OMCL Omnicell	3.2881 of 5 stars	$37.19 -1.2%	$57.86 +55.6%	+19.4%	$1.69B	$1.18B	44.27	3,580

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors